Production of inteleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432

1989 ◽  
Vol 21 (2) ◽  
pp. 127-130 ◽  
Author(s):  
Hiroyasu Fukui ◽  
Yasuo Koishihara ◽  
Masahiro Nagamuta ◽  
Yohichi Mizutani ◽  
Atsushi Uchida
Author(s):  
Melisa Gualdrón-López ◽  
Míriam Díaz-Varela ◽  
Haruka Toda ◽  
Iris Aparici-Herraiz ◽  
Laura Pedró-Cos ◽  
...  

The spleen is a secondary lymphoid organ with multiple functions including the removal of senescent red blood cells and the coordination of immune responses against blood-borne pathogens, such as malaria parasites. Despite the major role of the spleen, the study of its function in humans is limited by ethical implications to access human tissues. Here, we employed multiparameter flow cytometry combined with cell purification techniques to determine human spleen cell populations from transplantation donors. Spleen immuno-phenotyping showed that CD45+ cells included B (30%), CD4+ T (16%), CD8+ T (10%), NK (6%) and NKT (2%) lymphocytes. Myeloid cells comprised neutrophils (16%), monocytes (2%) and DCs (0.3%). Erythrocytes represented 70%, reticulocytes 0.7% and hematopoietic stem cells 0.02%. Extracellular vesicles (EVs) are membrane-bound nanoparticles involved in intercellular communication and secreted by almost all cell types. EVs play several roles in malaria that range from modulation of immune responses to vascular alterations. To investigate interactions of plasma-derived EVs from Plasmodium vivax infected patients (PvEVs) with human spleen cells, we used size-exclusion chromatography (SEC) to separate EVs from the bulk of soluble plasma proteins and stained isolated EVs with fluorescent lipophilic dyes. The integrated cellular analysis of the human spleen and the methodology employed here allowed in vitro interaction studies of human spleen cells and EVs that showed an increased proportion of T cells (CD4+ 3 fold and CD8+ 4 fold), monocytes (1.51 fold), B cells (2.3 fold) and erythrocytes (3 fold) interacting with PvEVs as compared to plasma-derived EVs from healthy volunteers (hEVs). Future functional studies of these interactions can contribute to unveil pathophysiological processes involving the spleen in vivax malaria.


Blood ◽  
1985 ◽  
Vol 65 (4) ◽  
pp. 990-996
Author(s):  
I Fabian ◽  
D Douer ◽  
L Levitt ◽  
Y Kletter ◽  
PL Greenberg

Mitogen-stimulated murine spleen cells produce humoral substances capable of supporting murine hematopoiesis and pluripotent stem cell proliferation in vitro. Thus, we evaluated conditioned media generated by human spleen cells (SCM) in the presence or absence of mitogens for factors stimulatory for human pluripotent (CFU-GEMM), erythroid (BFU- E), and myeloid (CFU-GM) precursors. Two and one half percent to 10% SCM stimulated proliferation of all three types of precursor cells from nonadherent buoyant human marrow target cells. Mitogen-stimulated SCM augmented CFU-GM (175% to 225%), whereas CFU-GEMM and BFU-E growth was essentially unchanged. Cell separation procedures used to determine which cells provided these microenvironmental stimuli indicated that nonadherent mononuclear spleen cells provided the bulk of the CSF-GM, whereas adherent cells (95% nonspecific esterase + monocyte- macrophages) and nonadherent cells provided similar proportions of CSF- mix and erythroid burst-promoting activity (BPA). The nonadherent cells generating high levels of CSF-mix, BPA, and CSF-GM were predominantly Leu-1-negative, ie, non-T, cells. In the presence or absence of mitogens, SCM was a more potent source (1.3- to 3.8-fold) than peripheral leukocyte CM of the growth factors for the three progenitor cell types. Specific in situ cytochemical stains for analyzing morphology of myeloid colonies demonstrated that SCM stimulated the proliferation of the same types and proportions of colonies as human placental CM, suggesting that these CMs may contain similar CSF-GMs. These data show the contribution of spleen cell subsets to the generation of hematopoietic growth factors and the responsiveness of these cells to various mitogenic stimuli.


1966 ◽  
Vol 53 (9) ◽  
pp. 794-798 ◽  
Author(s):  
M. O. Symes ◽  
A. G. Riddell
Keyword(s):  

1984 ◽  
Vol 160 (4) ◽  
pp. 1170-1183 ◽  
Author(s):  
R H Zubler ◽  
J W Lowenthal ◽  
F Erard ◽  
N Hashimoto ◽  
R Devos ◽  
...  

In this study we investigated whether interleukin 2 (IL-2) acts on B cell proliferation and whether activated B cells express IL-2 receptors. First, the functional activity of immunoaffinity-purified or recombinant human IL-2 was studied in a B blast assay using positively selected murine surface Ig-positive cells that had been activated by lipopolysaccharide (LPS) plus anti-Ig antibodies (anti-Ig). In this assay, T cells were not detected by fluorescence-activated cell sorter analysis. It was found that both IL-2 preparations led to optimal B cell proliferation compared with supernatants obtained from murine or human spleen cells or murine cloned T helper cells. Second, we observed that the IL-2 requirement in this assay was about the same as in a proliferation assay using lectin-activated polyclonal murine Lyt-2-positive T cells. Third, analysis of the binding of radiolabeled immunoaffinity-purified IL-2 to B cells indicated that LPS plus anti-Ig-activated B cells expressed a mean of 3,500 IL-2 receptors per cell with an apparent dissociation constant of 150 pM. However, neither nonactivated B cells nor B cells activated by LPS alone exhibited significant specific IL-2 binding. The functional and the receptor data are consistent with the conclusion that IL-2 is a growth factor not only for T cells but also for B cells.


PEDIATRICS ◽  
1991 ◽  
Vol 88 (3) ◽  
pp. 552-552
Author(s):  
J. F. L.

Two competitors, Centocor Inc. and Xoma Corp., are seeking clearance from the Food and Drug Administration for an entirely new sort of anti-infection drug... The new drugs, unlike antibiotics that act upon the bacteria, latch on to toxins made by the bacteria, thus blocking the next biochemical step in the disease process. Both drugs are monoclonal antibodies, proteins that zero in on selected targets in the body. Centoxin is derived from human spleen cells; Xoma's drug, called Xomen E-5, from mouse spleen cells. ... Some estimates... put the combined U.S. and European sales for both drugs at $750 million by the mid-1990s. One reason for the jumbo market projections is sky-high prices for drugs produced by biotechnology. Centoxin and Xomen-E5 both are expected to cost between $1,500 and $2,500 for a single course of treatment, given by injection.


1983 ◽  
Vol 106 (3) ◽  
pp. 202-209 ◽  
Author(s):  
Selman A. Ali ◽  
Catherine M. Hawrylowicz ◽  
Janet Peel ◽  
Clive Griffith ◽  
Robert C. Ress

Sign in / Sign up

Export Citation Format

Share Document